{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:57:25Z","timestamp":1775267845020,"version":"3.50.1"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of HL with unique clinicopathologic features. The hallmark histologic feature is the presence of malignant LP cells, unusual CD20+CD15\u2212CD30\u2212 variants of Reed-Sternberg cells, embedded within a nodular pattern of infiltrating lymphocytes. Compared with classical HL, NLPHL shows a slightly older median age at presentation (30\u201340 years), greater male predominance (3:1), less mediastinal involvement (&amp;lt;15%), and lower occurrence of classical HL risk factors. The differential diagnosis includes progressive transformation of germinal centers, lymphocyte-rich classical HL, and T-cell\/histiocyte-rich large B-cell lymphoma, the latter of which may share a common biologic relationship. The vast majority of patients present with limited stage disease (70%\u201380%), the standard treatment for which is involved field radiotherapy at 30\u201336 Gy. Response rates to primary therapy exceed 90%, although relapses are common and may occur years after the initial diagnosis. Secondary malignancies, particularly non-Hodgkin lymphoma, may also occur at a frequency similar to that of relapsed NLPHL. Patients with advanced stage disease may have lower response rates and overall survival times than those with limited stage disease. For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0099","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T02:25:34Z","timestamp":1247711134000},"page":"739-751","source":"Crossref","is-referenced-by-count":55,"title":["Nodular Lymphocyte Predominant Hodgkin Lymphoma"],"prefix":"10.1093","volume":"14","author":[{"given":"Alfred Ian","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,7,15]]},"reference":[{"key":"2021122207243225100_R1","first-page":"1","volume-title":"Cancer Facts & Figures 2008","year":"2008"},{"key":"2021122207243225100_R2","first-page":"628","article-title":"Significance of tissue lymphocytes in prognosis of lymphogranulomatosis","volume":"21","author":"Rosenthal","year":"1936","journal-title":"Arch Pathol"},{"key":"2021122207243225100_R3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1056\/NEJM194401062300101","article-title":"Hodgkin\u2019s disease. I. General considerations","volume":"230","author":"Jackson","year":"1944","journal-title":"N Engl J Med"},{"key":"2021122207243225100_R4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJM194407132310201","article-title":"Hodgkin\u2019s disease. II. Pathology","volume":"231","author":"Jackson","year":"1944","journal-title":"N Engl J Med"},{"key":"2021122207243225100_R5","volume-title":"Tumours of lymphoid tissue","author":"Lumb","year":"1954"},{"key":"2021122207243225100_R6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/1097-0142(195607\/08)9:4<792::AID-CNCR2820090429>3.0.CO;2-B","article-title":"Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases","volume":"9","author":"Hicks","year":"1956","journal-title":"Cancer"},{"key":"2021122207243225100_R7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.V11.3.211.211","article-title":"Mortality in relation to histologic type in Hodgkin\u2019s disease","volume":"11","author":"Smetana","year":"1956","journal-title":"Blood"},{"key":"2021122207243225100_R8","first-page":"944","article-title":"Relationship of histologic features to clinical stages in Hodgkin\u2019s disease","volume":"90","author":"Lukes","year":"1963","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2021122207243225100_R9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1964.03070230050014","article-title":"Hodgkin\u2019s disease. Prognosis and relationship of histologic features to clinical stage","volume":"190","author":"Lukes","year":"1964","journal-title":"JAMA"},{"key":"2021122207243225100_R10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jcp.14.3.219","article-title":"A clinicopathological study of benign Hodgkin\u2019s disease","volume":"14","author":"Dawson","year":"1961","journal-title":"J Clin Pathol"},{"key":"2021122207243225100_R11","first-page":"1063","article-title":"The pathology and nomenclature of Hodgkin\u2019s disease","volume":"26","author":"Lukes","year":"1966","journal-title":"Cancer Res"},{"key":"2021122207243225100_R12","first-page":"1311","article-title":"Report of the nomenclature committee","volume":"26","author":"Lukes","year":"1966","journal-title":"Cancer Res"},{"key":"2021122207243225100_R13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"2021122207243225100_R14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ajcp\/82.1.29","article-title":"Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin\u2019s disease","volume":"82","author":"Hsu","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"2021122207243225100_R15","first-page":"1","article-title":"Hodgkin\u2019s disease, lymphocyte predominance type, nodular\u2014a distinct entity? Unique staining profile for L&H variants of Reed-Sternberg cells defined by monoclonal antibodies to leukocyte common antigen, granulocyte-specific antigen, and B-cell-specific antigen","volume":"118","author":"Pinkus","year":"1985","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R16","first-page":"211","article-title":"Hodgkin\u2019s disease, lymphocyte predominance type, nodular\u2014further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker","volume":"133","author":"Pinkus","year":"1988","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R17","first-page":"244","article-title":"Leu-M1\u2014a marker for Reed-Sternberg cells in Hodgkin\u2019s disease. An immunoperoxidase study of paraffin-embedded tissues","volume":"119","author":"Pinkus","year":"1985","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R18","first-page":"508","article-title":"An evaluation of the utility of anti-granulocyte and anti-leukocyte monoclonal antibodies in the diagnosis of Hodgkin\u2019s disease","volume":"123","author":"Dorfman","year":"1986","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R19","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"2021122207243225100_R20","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"Fourth Edition"},{"key":"2021122207243225100_R21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X","article-title":"Hodgkin\u2019s disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin\u2019s lymphomas","volume":"51","author":"Miettinen","year":"1983","journal-title":"Cancer"},{"key":"2021122207243225100_R22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00390466","article-title":"Clinical features of nodular paragranuloma (Hodgkin\u2019s disease, lymphocyte predominance type, nodular)","volume":"108","author":"Hansmann","year":"1984","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122207243225100_R23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin\u2019s disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"key":"2021122207243225100_R24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1989.7.9.1303","article-title":"A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin\u2019s disease","volume":"7","author":"Borg-Grech","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0","article-title":"Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis","volume":"71","author":"Mauch","year":"1993","journal-title":"Cancer"},{"key":"2021122207243225100_R26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0360-3016(94)E0136-8","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes","volume":"31","author":"Crennan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122207243225100_R27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte predominant Hodgkin\u2019s disease. A clinical study of 50 cases","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdj037","article-title":"Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): Clinico-pathological characteristics and outcome of a rare entity","volume":"17","author":"de Jong","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"2021122207243225100_R29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/7.suppl_4.S61","article-title":"Lymphocyte predominant Hodgkin\u2019s disease\u2014a workshop report. European Task Force on Lymphoma","volume":"7","author":"Sextro","year":"1996","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R30","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199709051786","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease: Long-term observation reveals a continuous pattern of recurrence","volume":"26","author":"Orlandi","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"suppl 5","key":"2021122207243225100_R32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/annonc\/9.suppl_5.S39","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: Pathology and clinical implication","volume":"9","author":"Franklin","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R34","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"2021122207243225100_R35","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials","volume":"23","author":"Shimabukuro-Vornhagen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R36","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"2021122207243225100_R37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: A comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00000478-199405000-00014","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease. A distinct clinicopathological entity","volume":"18","author":"Mason","year":"1994","journal-title":"Am J Surg Pathol"},{"issue":"66","key":"2021122207243225100_R39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0609.2005.00456.x","article-title":"Special issues in pediatric Hodgkin\u2019s disease","author":"Schwartz","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"2021122207243225100_R40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"2021122207243225100_R41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0360-3016(98)00389-7","article-title":"Hodgkin\u2019s disease with lymphocyte predominance: Long-term results based on current histopathologic criteria","volume":"43","author":"Ha","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122207243225100_R42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood.V87.2.465.bloodjournal872465","article-title":"Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin\u2019s disease","volume":"87","author":"Falini","year":"1996","journal-title":"Blood"},{"key":"2021122207243225100_R43","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207243225100_R44","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.V84.10.3291.3291","article-title":"Lymphocyte predominance Hodgkin\u2019s disease: Lineage and clonality determination using a single-cell assay","volume":"84","author":"Delabie","year":"1994","journal-title":"Blood"},{"key":"2021122207243225100_R45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199708143370703","article-title":"Origin of nodular lymphocyte-predominant Hodgkin\u2019s disease from a clonal expansion of highly mutated germinal-center B cells","volume":"337","author":"Marafioti","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122207243225100_R46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199708143370704","article-title":"Clonality in nodular lymphocyte-predominant Hodgkin\u2019s disease","volume":"337","author":"Ohno","year":"1997","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122207243225100_R47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/13.S1.44","article-title":"Workshop on the relationship between nodular lymphocyte predominant Hodgkin\u2019s lymphoma and T cell\/histiocyte-rich B cell lymphoma","volume":"13","author":"Rd\u0308iger","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.pas.0000194741.87798.45","article-title":"IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma","volume":"30","author":"Prakash","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2021122207243225100_R49","first-page":"701","article-title":"Expression of B-cell antigens by Hodgkin\u2019s and Reed-Sternberg cells","volume":"139","author":"Schmid","year":"1991","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ajcp\/86.3.292","article-title":"Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin\u2019s disease of nodular subtype contain J chain","volume":"86","author":"Stein","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"2021122207243225100_R51","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V97.6.1845","article-title":"Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances","volume":"97","author":"Franke","year":"2001","journal-title":"Blood"},{"key":"2021122207243225100_R52","first-page":"965","article-title":"Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin\u2019s lymphoma","volume":"89","author":"Wlodarska","year":"2004","journal-title":"Haematologica"},{"key":"2021122207243225100_R53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1525-1578(10)60564-8","article-title":"Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin\u2019s lymphoma reveal a recurrent IGH-BCL6 juxtaposition","volume":"7","author":"Renn\u00e9","year":"2005","journal-title":"J Mol Diagn"},{"key":"2021122207243225100_R54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2003-05-1487","article-title":"Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease","volume":"103","author":"Marafioti","year":"2004","journal-title":"Blood"},{"key":"2021122207243225100_R55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1309\/Y8KD32QGRYFN1XQX","article-title":"A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma","volume":"126","author":"Rahemtullah","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2021122207243225100_R56","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1080\/10428190802308728","article-title":"Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma","volume":"49","author":"Rahemtullah","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122207243225100_R57","first-page":"351","article-title":"The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin\u2019s disease","volume":"135","author":"Poppema","year":"1989","journal-title":"Am J Pathol"},{"key":"2021122207243225100_R58","first-page":"139","volume-title":"Cytokines and cytokine receptors in Hodgkin\u2019s disease","author":"Kadin","year":"1999"},{"key":"2021122207243225100_R59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/path.1894","article-title":"Cytokine gene expression profile distinguishes CD4+\/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin\u2019s lymphoma from their tonsillar counterparts","volume":"208","author":"Atayar","year":"2006","journal-title":"J Pathol"},{"key":"2021122207243225100_R60","first-page":"19","article-title":"[Lymphocytes and their functional forms\u2014morphology, organization and immunologic significance]","volume":"69","author":"Lennert","year":"1975","journal-title":"Verh Anat Ges"},{"key":"2021122207243225100_R61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V97.3.714","article-title":"B-cell development in progressively transformed germinal centers: Similarities and differences compared with classical germinal centers and lymphocyte-predominant Hodgkin disease","volume":"97","author":"Br\u00e4uninger","year":"2001","journal-title":"Blood"},{"key":"2021122207243225100_R62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00000478-199203000-00005","article-title":"Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin\u2019s disease","volume":"16","author":"Ferry","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"2021122207243225100_R63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1309\/UUEPLF2PHYXQDJNQ","article-title":"Follicular hyperplasia, follicular lysis, and progressive transformation of germinal centers. A sequential spectrum of morphologic evolution in lymphoid hyperplasia","volume":"120","author":"Chang","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2021122207243225100_R64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2559.1979.tb03011.x","article-title":"Hodgkin\u2019s disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres\u2014a cytohistological study","volume":"3","author":"Poppema","year":"1979","journal-title":"Histopathology"},{"key":"2021122207243225100_R65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00000478-198410000-00001","article-title":"Clinical implications of progressive transformation of germinal centers","volume":"8","author":"Osborne","year":"1984","journal-title":"Am J Surg Pathol"},{"key":"2021122207243225100_R66","first-page":"135","article-title":"Progressive transformation of germinal centers: Comparison of 23 pediatric patients to the adult population","volume":"5","author":"Osborne","year":"1992","journal-title":"Mod Pathol"},{"key":"2021122207243225100_R67","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.11-4-384","article-title":"T-cell\/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and management","volume":"11","author":"Abramson","year":"2006","journal-title":"The Oncologist"},{"key":"2021122207243225100_R68","first-page":"88","article-title":"Segmental staining of the murine nephron by monoclonal antibodies directed against the GP-2 subunit of laminin","volume":"51","author":"Jaffe","year":"1984","journal-title":"Lab Invest"},{"key":"2021122207243225100_R69","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/1097-0142(19851001)56:7<1578::AID-CNCR2820560719>3.0.CO;2-L","article-title":"B-cell lymphomas morphologically resembling T-cell lymphomas","volume":"56","author":"Mirchandani","year":"1985","journal-title":"Cancer"},{"key":"2021122207243225100_R70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00000478-198806000-00003","article-title":"T-cell-rich B-cell lymphoma","volume":"12","author":"Ramsay","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"2021122207243225100_R71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00000478-199201000-00006","article-title":"Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin\u2019s disease, paragranuloma subtype","volume":"16","author":"Delabie","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"2021122207243225100_R72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2559.1991.tb00024.x","article-title":"Large B-cell lymphoma rich in T-cells and simulating Hodgkin\u2019s disease","volume":"19","author":"Chittal","year":"1991","journal-title":"Histopathology"},{"key":"2021122207243225100_R73","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2003.06.046","article-title":"T-cell\/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: A matched-control analysis","volume":"21","author":"Bouabdallah","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122207243225100_R74","first-page":"83","article-title":"Non-Hodgkin\u2019s lymphoma arising in patients treated for Hodgkin\u2019s disease in the BNLI: A 20-year experience. British National Lymphoma Investigation","volume":"2","author":"Bennett","year":"1991","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V88.2.657.bloodjournal882657","article-title":"Nodular lymphocyte-predominant Hodgkin\u2019s disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction","volume":"88","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"2021122207243225100_R76","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312","article-title":"Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage","volume":"86","author":"Wickert","year":"1995","journal-title":"Blood"},{"key":"2021122207243225100_R77","volume-title":"NCCN Practice Guidelines in Oncology. Hodgkin Disease\/Lymphoma 2009","author":"National Comprehensive Cancer Network"},{"key":"2021122207243225100_R78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/COC.0b013e318145b9db","article-title":"Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida","volume":"30","author":"Chera","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"2021122207243225100_R79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1053-4296(96)80018-X","article-title":"Long-term complications of treatment and causes of mortality after Hodgkin\u2019s disease","volume":"6","author":"Hancock","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"2021122207243225100_R80","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"key":"2021122207243225100_R81","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"2021122207243225100_R82","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogov\u00e1","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122207243225100_R83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semradonc.2007.02.004","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma","volume":"17","author":"Tsai","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"2021122207243225100_R84","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"2021122207243225100_R85","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/10428199909169633","article-title":"Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin\u2019s disease after administration of rituximab (anti CD 20 mono-clonal antibody) and interleukin-2","volume":"35","author":"Keilholz","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2021122207243225100_R86","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1365-2141.2001.02924-3.x","article-title":"Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin\u2019s disease: Long-term follow-up of allografting and monoclonal antibody therapy","volume":"114","author":"Lush","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122207243225100_R87","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"2021122207243225100_R88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"2021122207243225100_R89","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00043426-200309000-00003","article-title":"Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents","volume":"25","author":"Murphy","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122207243225100_R90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma\u2014experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-K\u00f6rholz","year":"2007","journal-title":"Cancer"},{"key":"2021122207243225100_R91","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin\u2019s lymphoma in children: Therapeutic abstention after initial lymph node resection\u2014a study of the French Society of Pediatric Oncology","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207243225100_R92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/(SICI)1096-911X(199712)29:6<519::AID-MPO1>3.0.CO;2-N","article-title":"Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment\u2014the Pediatric Oncology Group experience","volume":"29","author":"Karayalcin","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"2021122207243225100_R93","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00043426-200205000-00010","article-title":"Lymphocyte-predominant Hodgkin disease in children","volume":"24","author":"Sandoval","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122207243225100_R94","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1080\/10428190600573291","article-title":"High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin\u2019s lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only","volume":"47","author":"van Grotel","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122207243225100_R95","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2141.2007.06736.x","article-title":"Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma\u2014a Children\u2019s Cancer and Leukaemia Group report","volume":"138","author":"Hall","year":"2007","journal-title":"Br J Haematol"},{"key":"2021122207243225100_R96","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1080\/10428190600709507","article-title":"Treatment strategies for pediatric nodular lymphocyte predominant Hodgkin\u2019s lymphoma","volume":"47","author":"Vassilakopoulos","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122207243225100_R97","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/10428190500236502","article-title":"Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab","volume":"46","author":"Unal","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"2021122207243225100_R98","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V108.11.2471.2471","article-title":"Treatment of children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma with a low intensity short duration chemotherapy regimen [CVP]\u2014on behalf of the EuroNet-PHL group","volume":"208","author":"Shankar","year":"2006","journal-title":"Blood"},{"key":"2021122207243225100_R99","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"2021122207243225100_R100","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/7\/739\/41841128\/oncolo_14_7_739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/7\/739\/41841128\/oncolo_14_7_739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:46:50Z","timestamp":1640162810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/7\/739\/6397951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":100,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,7,15]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0099","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,7,1]]},"published":{"date-parts":[[2009,7,1]]}}}